As Australia’s biologics landscape continues to evolve, innovation remains central to improving patient outcomes, increasing healthcare efficiencies, and ensuring the sustainable use of donor tissue. Australian Allografts is committed to remaining at the forefront of technical advancement and is actively pursuing opportunities to introduce new processing technologies that expand product capabilities while improving operational efficiency.
A key milestone in this journey is our partnership with Texere Biotech, a global leader in advanced allograft processing technologies. Together, Australian Allografts and Texere Biotech are working to introduce world-class robotic processing solutions to the Australian allograft market, bringing a new level of precision, consistency, and innovation to tissue processing.
A Shared Vision for Innovation
The partnership is built on a shared commitment to advancing the science of tissue banking and maximising the life-changing impact of donated tissue.
According to Denis Dufrane of Texere Biotech:
“Texere Biotech is proud to partner with Australian Allografts and together we look forward to introducing our world’s best-practice robotic processing to the Australian allograft market. Our cutting-edge technology will revolutionise the art of allograft production, ensuring maximum recovery ratios whilst minimising the need for imported tissue and synthetic substitutes.”
This collaboration represents an important step forward for the Australian healthcare sector by combining international expertise with a local commitment to tissue stewardship and patient care.
Transforming Allograft Processing
Advanced robotic processing technologies offer significant benefits for tissue banking and allograft production, including:
- Greater processing consistency and quality
- Improved recovery and utilisation of donated tissue
- Enhanced operational efficiencies
- Expanded opportunities for product development
- Reduced reliance on imported tissue and synthetic alternatives
By embracing innovative processing methods, Australian Allografts aims to maximise the value of every donor gift while supporting clinicians with access to high-quality biological solutions.
Setting New Standards in Tissue Safety
Texere Biotech has also achieved an important industry milestone with its TMBG™ (Texere Machined Bone Graft) products becoming the world’s first bone allograft products certified as COVID-free.
To independently validate the effectiveness of its Bonefide® pathogen reduction process against enveloped viruses such as SARS-CoV-2, Texere Biotech engaged TEXCELL, a globally recognised contract research organisation specialising in viral testing, viral clearance, and biological safety assessments.
Independent testing confirmed that the Bonefide® process, combining physical processing, chemical treatments, and terminal sterilisation through irradiation, achieved virus removal and inactivation levels exceeding 11.0 log10. This significantly exceeds accepted standards for viral safety and provides confidence that TMBG™ grafts eliminate the risk of COVID-19 transmission to both surgeons and patients.
This achievement highlights the importance of continual investment in innovation, quality assurance, and evidence-based processing technologies.
Looking Towards the Future
The partnership between Australian Allografts and Texere Biotech represents more than technological advancement. It reflects a shared commitment to collaboration, scientific excellence, and improved patient outcomes.
Over the coming years, both organisations look forward to working with specialist Australian surgeons and healthcare professionals to further evaluate and document the benefits of advanced processing technologies through clinical research and peer-reviewed publications.
By bringing world-leading innovation to Australia, Australian Allografts continues its mission to support clinicians, maximise the impact of tissue donation, and contribute to the future of biologics and regenerative medicine.